statistiche ricercatore

COSCIA, MARTA

Distribuzione geografica

Continente	#
NA - Nord America	7.589
AS - Asia	3.908
EU - Europa	1.799
SA - Sud America	541
Continente sconosciuto - Info sul continente non disponibili	243
AF - Africa	95
OC - Oceania	10
Totale	14.185

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	7.326
SG - Singapore	1.838
CN - Cina	688
IT - Italia	635
HK - Hong Kong	620
BR - Brasile	445
VN - Vietnam	323
GB - Regno Unito	283
FR - Francia	239
RU - Federazione Russa	233
BD - Bangladesh	158
FI - Finlandia	110
CA - Canada	107
DE - Germania	96
MX - Messico	93
IN - India	74
NG - Nigeria	38
IQ - Iraq	32
NL - Olanda	30
TR - Turchia	30
ZA - Sudafrica	28
AR - Argentina	26
JP - Giappone	26
SE - Svezia	26
ES - Italia	23
AT - Austria	22
PL - Polonia	20
LT - Lituania	19
SA - Arabia Saudita	18
VE - Venezuela	17
CO - Colombia	16
IE - Irlanda	13
PK - Pakistan	13
CR - Costa Rica	12
EC - Ecuador	12
ID - Indonesia	12
JM - Giamaica	11
UA - Ucraina	11
UZ - Uzbekistan	11
CL - Cile	10
MD - Moldavia	10
MY - Malesia	10
AU - Australia	9
NP - Nepal	8
CH - Svizzera	7
EE - Estonia	7
HN - Honduras	7
KE - Kenya	7
PH - Filippine	7
TT - Trinidad e Tobago	7
AE - Emirati Arabi Uniti	6
JO - Giordania	6
BB - Barbados	5
EG - Egitto	5
GT - Guatemala	5
BS - Bahamas	4
MA - Marocco	4
SV - El Salvador	4
TN - Tunisia	4
BE - Belgio	3
BO - Bolivia	3
CZ - Repubblica Ceca	3
IL - Israele	3
IR - Iran	3
NI - Nicaragua	3
PE - Perù	3
PS - Palestinian Territory	3
PY - Paraguay	3
BG - Bulgaria	2
CY - Cipro	2
DZ - Algeria	2
ET - Etiopia	2
GR - Grecia	2
GY - Guiana	2
KG - Kirghizistan	2
KR - Corea	2
LB - Libano	2
OM - Oman	2
PR - Porto Rico	2
SR - Suriname	2
UY - Uruguay	2
AM - Armenia	1
BH - Bahrain	1
CI - Costa d'Avorio	1
DK - Danimarca	1
DO - Repubblica Dominicana	1
HU - Ungheria	1
KH - Cambogia	1
KN - Saint Kitts e Nevis	1
KZ - Kazakistan	1
LK - Sri Lanka	1
LV - Lettonia	1
LY - Libia	1
MT - Malta	1
NZ - Nuova Zelanda	1
PT - Portogallo	1
QA - Qatar	1
SN - Senegal	1
SY - Repubblica araba siriana	1
TG - Togo	1
Totale	13.938

Salva come PNG Salva come JPEG

Città	#
San Jose	1.899
Singapore	1.020
Ashburn	884
Council Bluffs	878
Hong Kong	610
Chicago	486
Dallas	395
The Dalles	257
Boardman	236
Beijing	216
Lauterbourg	196
London	193
Santa Clara	142
Los Angeles	138
Ho Chi Minh City	120
New York	115
Naples	114
Helsinki	94
Hanoi	80
Orem	76
Mexico City	71
Catania	67
São Paulo	57
Brooklyn	48
San Francisco	45
Atlanta	42
Denver	40
Milan	39
Abuja	38
Rome	37
Houston	29
Montreal	29
Phoenix	29
Munich	28
Toronto	28
Chennai	27
Nuremberg	27
Assago	26
Manchester	26
Tokyo	25
Frankfurt am Main	22
Johannesburg	21
Boston	20
Stockholm	20
Da Nang	19
Seattle	19
Warsaw	18
Buffalo	17
Shanghai	17
Guangzhou	16
Poplar	16
Salt Lake City	16
Haiphong	15
Ankara	14
Turku	14
Baghdad	13
Dublin	13
Shenzhen	13
Rio de Janeiro	12
San José	12
Amsterdam	11
Belo Horizonte	11
Calgary	11
Hangzhou	11
Tashkent	11
Tianjin	11
Porto Alegre	10
Charlotte	9
Elk Grove Village	9
Flanders	9
Miami	9
Philadelphia	9
Riyadh	9
Secaucus	9
Vergiate	9
Washington	9
Bologna	8
Chandler	8
Düsseldorf	8
Moscow	8
Oklahoma City	8
Vienna	8
Brasília	7
Caracas	7
Detroit	7
Honolulu	7
Indianapolis	7
Juneau	7
Las Vegas	7
Mumbai	7
Nairobi	7
New Delhi	7
Ottawa	7
Zhengzhou	7
Amman	6
Cavaria con Premezzo	6
Concord	6
Contagem	6
Fairfield	6
Fort Worth	6
Totale	9.559

Salva come PNG Salva come JPEG

Nome	#
Pre-existing and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs	605
AISF position paper on HCV in immunocompromised patients	160
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY	101
The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL)	100
MAKING THE RIGHT CHOICE: THE ROLE OF FITNESS STATUS IN THE MANAGEMENT OF FIRST-LINE TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL FITNESS STUDY)	96
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: a retrospective real‐life multicenter Italian cohort	89
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study	88
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia	88
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target	87
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma	86
Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway	83
A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia	82
Progressive telomere shortening occurs during the natural history of chronic lymphocytic leukemia (CLL) and associates to outcome	79
Autoimmune complications in chronic lymphocytic leukemia in the era of targeted drugs	79
B-cell Acute Lymphoblastic Leukemia in Patients with Chronic Lymphocytic Leukemia Treated with Lenalidomide	79
Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study	78
SLAMF1/CD150 IS A SIGNALING RECEPTOR EXPRESSED BY A SUBSET OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS CHARACTERIZED BY A FAVORABLE PROGNOSIS	77
AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING BENDAMUSTINE PLUS RITUXIMAB TREATMENT IN CLL PATIENTS	76
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials	76
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: A GIMEMA, ERIC and UK CLL FORUM study	76
Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience	76
The metabolism of mevalonate as a signaling pathway influencing tumor-host interactions and disease progression in chronic lymphocytic leukemia (CLL)	76
Immune dysfunctions and immune-based therapeutic interventions in chronic lymphocytic leukemia	75
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia	75
Abstract 2072: Selinexor in combination with chemotherapy or idelalisib elicits a synergistic cytotoxic effect in primary CLL cells	75
Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation	74
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study	74
Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment	73
BTK and PLCG2 remain unmutated in one third of patients with CLL relapsing on ibrutinib	72
Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives	72
The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice	71
Treatment of chronic lymphocytic leukemia in the new drugs era: the state of art in the Italian landscape	71
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: Correlation with biologically-based risk stratification	71
Adenosine Signaling Mediates Hypoxic Responses in the Chronic Lymphocytic Leukemia Microenvironment	71
A PHASE II MULTI-CENTER TRIAL OF PENTOSTATIN PLUS CYCLOPHOSPHAMIDE WITH OFATUMUMAB (PCO) IN OLDER PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS	71
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study	71
Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy	71
AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING BENDAMUSTINE TREATMENT IN CLL PATIENTS	70
B-cell acute lymphoblastic leukemia (B-ALL) in CLL patients treated with lenalidomide	70
Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia	70
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study	70
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials	69
Accelerated activity of the mevalonate pathway supports the immune escape and multidrug-resistance phenotype of IGHV unmutated chronic lymphocytic leukemia cells	69
HLA-G is a component of the CLL escape repertoire to generate immune suppression: impact of HLA-G 14 bp (rs66554220) polymorphism	69
Final Report of Bendamustine and Alemtuzumab (BEN CAM) Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia	69
Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia	69
Targeting the mevalonate pathway and downstream signaling pathways as a strategy to circumvent multidrug-resistance in CLL cells	68
LDH Levels Predict Progression-Free Survival in Treatment-NaIVe Patients with Trisomy 12 Chronic Lymphocytic Leukemia	67
IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF ANTIBODY IMMUNE RESPONSES ELICITED BY SELF ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKEMIA	67
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THE IDENTIFICATION OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY-RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA	67
Slamf-1/CD150 Is a Signaling Receptor Expressed by a Subset of Chronic Lymphocytic Leukemia Patients Characterized by a Favorable Prognosis	66
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells	65
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino	65
Immunotherapeutic strategies in chronic lymphocytic leukemia: advances and challenges	65
Zoledronic acid impairs mammary carcinogenesis in BALB/c mice transgenic for the Her-2/neu oncogene	65
Expression of telomeric proteins in chronic lymphocytic leukemia (CLL)	64
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL	64
Impact of immune parameters and immune dysfunctions on the prognosis of patients with chronic lymphocytic leukemia	64
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study	64
Mutations in NOTCH1 PEST Domain Orchestrate CCL19-Driven Homing of Chronic Lymphocytic Leukemia (CLL) Cells By Modulating the Gene DUSP22	63
The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy	63
Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: Multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials	62
TARGETING HIF-1 AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER TUMOR-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA	62
TELOMERES SHORTEN DURING CHRONIC LYMPHOCYTIC LEUKEMIA(CLL) EVOLUTION: AN ANALYSIS ON 88 CASES	62
The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespective of the disease status	62
Effective anti-tumor immunomodulatory properties of zoledronic acid	62
BENDAMUSTINE AND ALEMTUZUMAB (BEN CAM) COMBINATION IN RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): PRELIMINARY REPORT OF THE ITALIAN TRIAL	62
The Mevalonate Metabolic Pathway and the CXCL12/CXCR4 Axis Reciprocally Interact and Are Implicated in Fludarabine Resistance of Chronic Lymphocytic Leukemia Cells	62
Identification and functional characterization of tumor specific antibody responses in chronic lymphocytic leukemia	61
Bendamustine and alemtuzumab (BEN CAM) combination in relapsed and refractory chronic lymphocytic leukaemia (CLL): interim report of the italian trial	61
IGHV UNMUTATED CLL B CELLS ARE MORE PRONE TO SPONTANEOUS APOPTOSIS AND DEPEND FROM THE ANTI-APOPTOTIC EFFECT OF ENVIRONMENTAL SIGNALS	61
THE SURVIVAL OF TUMOR CELLS IN IGVH UNMUTATED CHRONIC LYMPHOCYTIC LEUKEMIA IS HIGHLY DEPENDENT ON EXOGENOUS SIGNALS DELIVERED BY THE TUMOR MICROENVIRONMENT	61
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study	61
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells	61
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study	60
Beyond ibrutinib: novel BTK inhibitors for the treatment of chronic lymphocytic leukemia	60
Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications	60
TARGETING HIF-1A AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER LEUKEMIA-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA	60
High rate of durable responses with undetectable minimal residual disease with frontline venetoclax and rituximab in young and fit patients with chronic lymphocytic leukemia and an adverse biologic profile: results of the gimema phase II LLC1518 - 'Veritas' study	59
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus	59
OXIDATIVE STRESS IN CHRONIC LYMPHOCYTIC LEUKEMIA	59
Prognostic significance of PET/CT in patients with chronic lymphocytic leukemia (CLL) treated with frontline chemoimmunotherapy	59
Myeloma cells drive the maturation of dendritic cells versus a Th2-promoting phenotype which impairs T-cell activation	59
PROGRESSIVE TELOMERE SHORTENING DURING THE NATURAL HISTORY OF CHRONIC LYMPHOCYTIC LEUKEMIA	59
Increased expression of non-functional killer inhibitory receptor CD94 in CD8+ cells of myeloma patients	58
THE LOCAL MICROENVIRONMENT PLAYS A DIFFERENT ROLE IN THE SURVIVAL OF TUMOR CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH MUTATED AND UNMUTATED IMMUNOGLOBULIN (IG) VH GENES	58
SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response	58
FIRST-LINE TREATMENT CHOICE FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: WHAT DO CLINICIANS CARE ABOUT? THE CLL FITNESS STUDY	58
IMPACT OF THE MEVALONATE PATHWAY AND HIF/PGP AXIS IN MODULATING MULTIDRUG-RESISTANCE IN UNMUTATED CLL CELLS	58
Telomere lenght measurement in the clinically oriented research setting: a comparison between Southern blot (SB), real time quantitative PCR (RQ-PCR) and FLOW-FISH (FF)	58
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia	58
Chlorambucil PLUS Rituximab As FRONT-LINE Therapy for Elderly and/or Unfit CLL Patients. LONG-TERM Follow-up and Correlation with Biologic-Based Risk Stratification	58
Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells	58
The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status	58
Pre-Existing and Treatment-Emergent Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Drugs	58
Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia	58
The PD-1/PD-L1 Axis Contributes to T Cell Dysfunction in Chronic Lymphocytic Leukemia	57
Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights	57
Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study	57
Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T cells	57
Totale	7.444

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	68.627
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	68.627

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	5	0	0	0	0	0	0	0	1	1	1	1	1
2022/2023	23	2	1	3	1	3	3	0	3	5	0	0	2
2023/2024	27	4	5	5	5	6	0	0	1	0	0	0	1
2024/2025	3.434	239	34	868	158	181	118	136	111	283	200	222	884
2025/2026	8.412	411	465	436	846	458	399	2.377	348	788	536	945	403
2026/2027	2.249	245	353	1.027	624	0	0	0	0	0	0	0	0
Totale													14.185